PMID- 1926318
OWN - NLM
STAT- MEDLINE
DCOM- 19911112
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 31
IP  - 8
DP  - 1991 Oct
TI  - Serologic distinction between human T-lymphotropic virus (HTLV) type I and HTLV 
      type II.
PG  - 731-6
AB  - In November 1988, the Food and Drug Administration approved reagents for 
      serologic screening for human T-lymphotropic virus type I (HTLV-I) infection in 
      blood donors and patients suspected of having HTLV-I-related illnesses. These 
      reagents are able to detect HTLV type II (HTLV-II), a close relative of HTLV-I 
      with no known pathologic effect. The distinction between the two forms of HTLV is 
      important to the donor and to any recipient of blood containing HTLV. The 
      application to sera from 38 seropositive blood donors and 2 recipients (37 
      "confirmed" positive and 3 indeterminate by Western blot) of two methods (Western 
      blot and peptide enzyme immunoassay) for serologic distinction between HTLV-I and 
      -II is described. These results were compared to those from polymerase chain 
      reaction (PCR) analysis of HTLV proviral DNA obtained from donor peripheral blood 
      mononuclear cells. The peptide enzyme immunoassay was found to be less sensitive 
      than the Western blot, but completely concordant with PCR results when 
      differential reactivity could be established. The Western blot pattern showed 
      complete diagnostic concordance with the samples with confirmed-positive 
      serologic tests, but was incorrect in two HTLV-II-infected donors with 
      indeterminate serologic tests. Thirty-three (89%) of the 37 individuals from this 
      predominantly Native American and Hispanic group of blood donors were found to 
      have HTLV-II. These findings confirm and extend previous reports that HTLV-I 
      infection may be less common, and HTLV-II infection more common, than previously 
      believed. The peptide enzyme immunoassay can provide most individuals who have 
      positive results with the HTLV-I/II screening test with serologic distinction 
      between HTLV-I and HTLV-II.
FAU - Hjelle, B
AU  - Hjelle B
AD  - Department of Pathology, University of New Mexico School of Medicine, 
      Albuquerque.
FAU - Cyrus, S
AU  - Cyrus S
FAU - Swenson, S
AU  - Swenson S
FAU - Mills, R
AU  - Mills R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
SB  - IM
MH  - Blood Donors
MH  - Blotting, Western
MH  - Human T-lymphotropic virus 1/*classification
MH  - Human T-lymphotropic virus 2/*classification
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Polymerase Chain Reaction
MH  - Serotyping
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 10.1046/j.1537-2995.1991.31892023499.x [doi]
PST - ppublish
SO  - Transfusion. 1991 Oct;31(8):731-6. doi: 10.1046/j.1537-2995.1991.31892023499.x.